View Special Meeting Documentation
Number of common stock shares in issue: 30,658,603 shares are issued, called up and fully paid. The Company holds no shares in treasury.
| Significant shareholders | No of Common Shares | % of share capital |
| Cable Car Capital LLC | 6,798,586 | 22.2 |
| Simon Raab | 4,148,293 | 13.5 |
| Unicorn Asset Management | 3,907,142 | 12.7 |
| Icahn School of Medicine at Mount Sinai | 2,469,842 | 8.0 |
| Octopus Investments | 1,968,750 | 6.4 |
| Frederick Gluck | 1,757,353 | 5.7 |
| Livzon Pharmaceutical Group Inc | 1,347,653 | 4.4 |
| Accord Data Holdings | 954,048 | 3.1 |
| Director | No of Common Shares | % of share capital |
| Roy Davis | 42,775 | 0.13 |
| Andy Boteler | 19,966 | 0.07 |
| Paul Pagano | 26,408 | 0.09 |
| David Anderson | 26,408 | 0.09 |
Percentage of securities not in public hands: As of 28 May 2025 the percentage of common shares not in the public hands was 49.4%.
LungLife AI is not subject to the City Code because its registered office is outside the UK, the Channel Islands and the Isle of Man. As a result, certain of the protections that are afforded to shareholders under the City Code, for example in relation to a takeover of a company or certain stakebuilding activities by shareholders, do not apply to LungLife AI. Certain provisions have been inserted into LungLife AI’s Certificate of Incorporation that adopt similar procedures to the City Code in the event of any party (or parties acting in concert) obtaining 30 per cent or more of the voting rights attaching to the issued Ordinary Shares, but there is no assurance that the courts of Delaware will uphold or allow the enforcement of these provisions.
This page was last updated on: 29 May 2025
LungLife AI licensure/accreditation information posted here.